BPA Screening: information you need

BPA screening helps identify bisphenol A exposure and its potential effects on your endocrine system by combining accurate hormone testing with specialized BPA diagnostics. Our approach delivers clear, actionable results and expert interpretation so you can understand exposure levels, assess hormone disruption risks, and take informed steps for comprehensive endocrine health monitoring.

How to interpret your results

A BPA or phthalates result is almost always reported as a concentration in urine — usually nanograms per milliliter (ng/mL) or micrograms per liter (µg/L) of the parent compound or its metabolite. Because nearly all Americans have detectable levels of these chemicals in their urine, the question is rarely “is it present?” but “how does my level compare to the general population?”

The most widely used population yardstick is the CDC National Report on Human Exposure to Environmental Chemicals, which publishes biomonitoring data from the National Health and Nutrition Examination Survey (NHANES). Because of how NHANES is designed, the measurements are representative of exposures in the U.S. civilian population. Labs typically express your result against percentile cutoffs (50th, 75th, 90th, 95th) from this dataset for your age and sex group.

What “elevated” actually means here

A result above the 95th percentile means your exposure is higher than 95% of people in the NHANES sample. That is meaningful biological signal, but it is not the same as a clinical diagnosis. The CDC explicitly states that the Report does not provide health or toxicity information, reference ranges in the clinical sense, or regulatory guidelines. Biomonitoring tells you about exposure, not about disease.

A few interpretive points flow from the source biology:

• Phthalates have short biological half-lives — about 12 hours. BPA likewise clears the body within roughly a day through urinary excretion. A single test reflects recent exposure, often from the last day or two, not a long-term burden.
• Many labs report not the parent phthalate but its metabolites (for example, MEHP, MECPP, or MCMHP for DEHP), because these are what actually appear in urine and serum after hydrolysis and conjugation.
• A single high value should usually be repeated — short half-lives mean today’s exposure can swamp last week’s average.

Sources of BPA and phthalate exposure in everyday life

BPA and phthalates are different chemical families, but they share one feature: they are everywhere a plastic touches a person. Knowing the major exposure routes is the most useful thing biomonitoring gives you, because it tells you what to look at if your result comes back elevated.

BPA is found in many plastics and epoxy resins, and in products ranging from infant bottles to water pipes. Most individuals are exposed to BPA through diet because the chemical is used widely in food packaging, bottle tops, and related products; exposure can also occur via air, dust, and water.

Phthalates sit in a wider set of products because the lower-molecular-weight forms (DEP, DMP) are used in personal care, while the higher-molecular-weight forms (DEHP, DBP, DiNP) are used as plasticizers in PVC. Common sources documented in the toxicology literature:

People are exposed mainly through ingestion, inhalation, and dermal contact, with personal care products being a notable dermal route. Fatty foods like dairy and meat tend to absorb more phthalates from packaging, and dust ingestion is a meaningful pathway for small children. The early-2000s NHANES survey found that almost all Americans had BPA in their urine, which is what put the scale of population exposure on the map.

The science behind BPA and phthalates as endocrine disruptors

These chemicals are tested because they belong to a class called endocrine-disrupting chemicals (EDCs) — substances that interfere with normal hormone signaling. BPA is called an endocrine disruptor because of its ability to alter hormone activity. Phthalates are characterized the same way: a series of chemicals that “demonstrate to be endocrine disruptors and are detrimental to human health”.

Mechanisms documented in research

Endocrine disruption is not a single mechanism. The literature describes several overlapping pathways:

• Hormone-receptor activity. Researchers in the CLARITY-BPA program observed alterations in the expression of estrogen and androgen receptors in rat brain tissue after low-dose BPA exposure.
• Gene expression and methylation. High-molecular-weight phthalates have been linked to changes in the methylation status of imprinted genes, with downstream effects on androgen response, estrogen response, protein secretion, and spermatogenesis.
• Reproductive and developmental signaling. In rodent studies, phthalate toxicity concentrates in the liver, kidney, thyroid gland, and testis, and prenatal exposure has been linked to increased prenatal mortality, reduced birth weight, and skeletal and visceral malformations.

The low-dose question

A long-running controversy is whether very small, real-world exposures cause harm. The CLARITY-BPA project was designed in part to answer that. The FDA-led core study reported that relatively low BPA exposures produced essentially negative findings, while many NIEHS-funded university papers reported adverse health effects at low doses. The authors did not reach consensus, but the divergence is informative — it suggests current guideline-compliant studies “may not detect all potential hazards from real-world exposures to chemicals, especially hormone-disrupting substances such as BPA”.

For related hormonal markers that may be affected by chronic EDC exposure, the estradiol test and testosterone test cover the sex-hormone axes that endocrine disruptors most directly intersect with.

Reducing your BPA and phthalate exposure

Because both chemical families clear the body quickly, exposure reduction works — measured levels can decline within days to weeks of changing the inputs. The peer-reviewed phthalates literature outlines practical strategies that map cleanly onto consumer behavior:

• Use glass containers instead of plastic packaging for food storage, especially for hot, fatty, or acidic foods.
• Avoid heating food in plastic containers. Heat accelerates the leaching of plasticizers like DEHP into food.
• Read personal-care-product labels and avoid products with fragrance, since fragrance mixtures may contain phthalates.
• Use phthalate-free gloves, utensils, and packaging when processing food at home or at work.
• Choose DEHP-free medical devices where available — alternatives like polyethylene, polypropylene, silicone, and ethylene-vinyl acetate are increasingly used in Europe.

For BPA specifically, NIEHS documents the dominant routes (diet, plus air, dust, and water), so the highest-leverage changes are food-packaging swaps and reducing contact with epoxy-resin-lined cans.

Two caveats. “BPA-free” products are not automatically safer — substitute bisphenols and substitute plasticizers are still being studied, and recent biomonitoring shows decreasing phthalates alongside rising levels of phthalate alternatives in humans. The CLARITY-BPA findings on low-dose effects also caution against assuming that “below the regulatory threshold” means “biologically irrelevant”.

BPA, phthalates, and pregnancy or children

Pregnancy and early childhood are the windows where endocrine disruption matters most, because hormone signaling is shaping organ development. The toxicology evidence treats these groups as the population of highest concern.

Pregnancy

Phthalates cross the placenta-blood barrier, which makes the placenta a major exposure route for the fetus. In cumulative-risk modeling using NHANES data, the hazard index (a combined measure of exposure to multiple phthalates relative to tolerable daily intakes) exceeded 1 in about 10% of pregnant women — roughly one in ten women in the sample had combined phthalate exposure above the level considered acceptable. Adverse pregnancy-related associations in epidemiological studies include earlier menopause, low birth weight, pregnancy loss, and preterm birth.

Children

Children are more vulnerable than adults: higher intake per body weight, more hand-to-mouth contact with dust and toys, and developmental sensitivity. Reported pediatric impacts include effects on anogenital distance, semen quality in adolescents, precocious puberty, thyroid function, and neurodevelopment. A California study found 82–89% of children had DBP exposure exceeding reproductive health benchmarks, and 8–11% of children under two years exceeded cancer-risk benchmarks for DEHP. Specific exposure sources for kids include soft vinyl toys, old plastic toys, teething rings, and indoor dust in childcare settings.

For families considering hormonal workup alongside biomonitoring, the TSH test is the standard first-line marker for thyroid function — relevant because altered thyroid function is among the documented pediatric outcomes.

When to talk to your doctor

Biomonitoring data on its own does not establish that any individual has a disease — it only describes exposure. The CDC is explicit that its National Exposure Report does not provide health or toxicity information. Acting on a result is therefore a clinical conversation, not a lab-driven one. Bring a BPA or phthalate result into a clinical visit if any of the following apply:

• You are pregnant or planning a pregnancy and your urinary phthalate metabolites or cumulative hazard index sit in the upper population percentiles — pregnancy is the period where modeling has flagged exceedance in roughly 10% of women.
• You are a parent of an infant or young child with elevated urinary metabolites, given documented pediatric sensitivity to DEHP, DBP, and related compounds.
• You have a fertility, menstrual-cycle, or semen-quality concern alongside elevated phthalate metabolites — epidemiological studies link phthalates to altered reproductive hormones and semen quality.
• You have unexplained thyroid or metabolic findings (insulin resistance, weight changes, abnormal thyroid markers) alongside high BPA or phthalate results.
• You have occupational or environmental exposure (plastics manufacturing, frequent thermal-receipt handling, residence near plastics facilities) and want to document baseline and post-mitigation levels.

A clinician — primary care, endocrinology, or occupational/environmental medicine — can put your biomonitoring number in the context of your symptoms, other lab work, and exposure history, and decide whether repeat testing or additional hormone testing such as TSH, estradiol, or fasting glucose is warranted.

Frequently asked questions

How do I test for BPA in urine?

BPA is most commonly measured in a urine sample — often a first-morning or timed collection — with the parent compound or its metabolites quantified by mass spectrometry. Because BPA has a short biological half-life, the result reflects exposure from roughly the last 24 hours rather than long-term burden.

Can I test for BPA at home?

Some commercial kits collect urine at home and ship it to a laboratory for analysis. Collection is straightforward, but the analytical work requires a specialized lab. The available evidence does not validate any specific consumer kit; CDC NHANES data remains the standard population reference.

Is BPA tested in blood or urine?

Urine is the primary biomonitoring matrix for both BPA and phthalates because the chemicals are rapidly metabolized and excreted there. Some DEHP metabolites such as MCMHP have been measured in serum and are described as suitable biomarkers, but urine remains the dominant sample type.

How quickly does BPA leave the body?

Phthalates have a biological half-life of about 12 hours and are cleared mainly through urine and feces after hydrolysis and conjugation. BPA is similarly metabolized and excreted in urine on a scale of roughly a day, which is why repeat testing is often recommended to characterize ongoing exposure rather than a single snapshot.

Are “BPA-free” products actually safe?

Not automatically. The label only tells you about one chemical. Recent biomonitoring shows that as phthalate levels have declined in human samples, levels of phthalate alternatives have risen. Substitute compounds may share endocrine activity, so a “BPA-free” or “phthalate-free” label means “this specific compound is not present,” not “this product is biologically inert.”

Should pregnant women get tested?

There is no general screening recommendation, but pregnancy carries the clearest cumulative-risk signal: NHANES-based modeling found that the combined phthalate hazard index exceeded the acceptable threshold in roughly 10% of pregnant women. Discussing testing with an obstetric provider is reasonable if exposure history or symptoms warrant it.

Do phthalates get measured in the same test as BPA?

They are often offered as a combined panel because both are endocrine-disrupting chemicals leaching from plastics, but they are chemically different families and use different analytes. A combined panel typically reports BPA and several phthalate metabolites (often DEHP, DBP, DEP, and BBP metabolites) on one report.

Is there a recommended “safe” level of BPA?

The CDC Exposure Report does not set regulatory guidelines and does not define a “safe” level — it only describes population exposure. Regulatory tolerable daily intakes exist for some phthalates (the tolerable daily intake for DEHP referenced in toxicology reviews is 48 µg/kg body weight per day), but these are set by regulators, not by the biomonitoring program itself.

References

• Peer-reviewed reference
• Centers for Disease Control and Prevention (CDC)
• PubMed (U.S. National Library of Medicine, NIH)

Last reviewed: 2026-05-17